Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 17/20 | 0.53 |
| ▸ | MMP12 | P39900 | 17/20 | 0.53 |
| ▸ | MMP9 | P14780 | 15/20 | 0.53 |
| ▸ | MMP2 | P08253 | 12/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17261572 | 0.80 | MMP1 (0.53) | MMP1MMP12MMP9MMP2TDP1 | |
| SCHEMBL13571768 | 0.79 | MMP1 (0.52) | MMP1MMP12MMP9MMP2 | |
| SCHEMBL21322002 | 0.79 | MMP1 (0.52) | MMP1MMP12MMP9MMP2 | |
| SCHEMBL20206904 | 0.79 | MMP1 (0.56) | MMP1MMP12MMP9MMP2 | |
| SCHEMBL8190893 | 0.79 | MMP1 (0.47) | MMP1MMP12MMP9MMP2 | |
| SCHEMBL29620349 | 0.74 | MMP2 (0.54) | MMP1MMP12MMP9MMP2 | |
| SCHEMBL24112333 | 0.74 | MMP1 (0.51) | MMP1MMP12MMP9MMP2 | |
| SCHEMBL2897889 | 0.74 | MMP1 (0.47) | MMP1MMP12MMP9MMP2KDM4E | |
| SCHEMBL1161224 | 0.74 | MMP1 (0.66) | MMP1MMP12MMP9MMP2KDM4E | |
| SCHEMBL3724190 | 0.74 | MMP1 (0.51) | MMP1MMP12MMP9MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635567-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2015-10-28 | — | — | EP | claimed |
| US-20130217702-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. | 2013-08-22 | — | — | US | claimed |
| CN-103201276-A | Indole derivatives | RICHTER GEDEON NYRT | 2013-07-10 | — | — | CN | claimed |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | disclosed |
| US-12440584-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | LUMIPHORE, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4618755-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-09-02 | — | — | US | disclosed |
| CN-115066428-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4554574-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | The Scripps Research Institute (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119698278-A | Small molecule modulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases | 斯克里普斯研究学院 | 2025-03-25 | — | — | CN | disclosed |
| CN-119101040-B | Method for synthesizing aryl substituted chiral tetrahydropyran ring through desymmetrical synthesis | 杭州澳赛诺医药技术有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-7160907-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | disclosed |
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | US | disclosed |
| WO-2006106054-A1 | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CB1 INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |
| EP-1538150-A1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-08 | — | — | EP | disclosed |
| EP-1351959-B1 | NOVEL PLEUROMUTILIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-6900345-B2 | Pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-05-31 | — | — | US | disclosed |
| US-20050096357-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. | 2005-05-05 | — | — | US | disclosed |
| EP-1186598-B1 | Process of preparing 5-(2-substituted-4-nitrophenyl)-oxazole, oxazole compound, and process of preparing the same | NIPPON SYNTHETIC CHEM IND (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20040024059-A1 | Novel pleuromutilin derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217702-A1 | INDOLE DERIVATIVES | BDKRB1, BDKRB2, ARRB1 | MMP1 214/4885MMP12 1012/4885MMP9 1011/4885 |
| US-20040024059-A1 | Novel pleuromutilin derivatives | PLEC, MLNR, FABP2 | MMP1 3246/4885MMP12 1619/4885MMP9 2974/4885 |
| US-20060229326-A1 | Pyridine-3-carboxamide derivatives as CB1 inverse agonists | CNR1, CNR2, GPR119 | MMP1 4848/4885MMP12 4489/4885MMP9 4756/4885 |
| US-12440584-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | TFRC, CLTC, SLC39A3 | MMP1 4422/4885MMP12 1086/4885MMP9 3408/4885 |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | MMP1 4596/4885MMP12 1669/4885MMP9 3044/4885 |
| US-20050096357-A1 | Novel pleuromutilin derivatives | FABP2, PLEC, MLNR | MMP1 3107/4885MMP12 1149/4885MMP9 3139/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | MMP1 4341/4885MMP12 2416/4885MMP9 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.